To Evaluate the Safety and Efficacy of Inhaled CT-P63 and CT-P66 Combination Therapy in Symptomatic Patients With COVID-19 Not Requiring Supplemental Oxygen

Summary

This is a Phase 3 study to assess the efficacy about therapeutic effect of inhaled CT-P63 and CT-P66 combination therapy to symptomatic patiemts with COVID-19 and overall safety.

Timeline

Start

2022-04

Primary completion

2022-11

Completion

2023-01

Outcome

Outcome not reported

Stopped: “The sponsor has decided to stop development of the inhaled CT-P63/66 combination therapy.”

Drugs

Indications